Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56; P < 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent human studies have consistently shown that PD-L1 and PD-L2 expression not only increases in cancerous tissues but is also linked to poor disease prognosis in many cancer types (50)(51)(52)(53)(54)(55)(56).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The Heidelberg classification of renal cell tumours
Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,354
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Self-citationComparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00005 · Cited by 1,087
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
PANTUCK, A. J., ZISMAN, A., & BELLDEGRUN, A. S. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65640-6 · Cited by 882
Research works printed but not linked: 13
- Strome, S.-E., Dong, H., Tamura, H., Voss, S.-G., Flies, D.-B., Tamada, K., Salomao, D., Cheville, J.-C, Hirano, F., Lin, W., et al. (2003) Cancer Res. 63, 6501–6505. [PubMed] [Google Scholar]
- Graham, S., Babayan, R.-K., Lamm, D.-L., Sawczuk, I., Ross, S.-D., Lavin, P.-T., Osband, M.-E. & Krane, R.-J. (1993) Semin. Urol. 11, 27–34. [PubMed] [Google Scholar]
- Krejci, K.-G., Markiewicz, M.-A. & Kwon, E.-D. (2003) J. Urol. 171, 870–876. [DOI] [PubMed] [Google Scholar]
- Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) Cancer Res. 61, 5132–5136. [PubMed] [Google Scholar]
- Storkel, S., Eble, J.-N., Adlakha, K., Amin, M., Blute, M.-L., Bostwick, D.-G., Darson, M., Delahunt, B. & Iczkowski, K. (1997) Cancer 80, 987–989. [DOI] [PubMed] [Google Scholar]
- Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M. & Wiendl, H. (2003) Cancer Res. 63, 7462–7467. [PubMed] [Google Scholar]
- Uzzo, R.-G., Rayman, P., Kolenko, V., Clark, P.-E., Bloom, T., Ward, A.-M., Molto, L., Tannenbaum, C., Worford, L.-J, Bukowski, R.-M., et al. (1999) Clin. Cancer Res. 5, 1219–1229. [PubMed] [Google Scholar]
- Alexander, J.-P., Kudoh, S., Melsop, K.-A., Hamilton, T.-A., Edinger, M.-G., Tubbs, R.-R., Sica, D., Tuason, L., Klein, E., Bukowski, R., et al. (1993) Cancer. Res. 53, 1380–1387. [PubMed] [Google Scholar]
- Li, X., Liu, J., Park, J.-K., Hamilton, T.-A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R. & Finke, J. (1994) Cancer Res. 54, 5424–5429. [PubMed] [Google Scholar]
- Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R.-R., Novick, A., Finke, J.-H. & Bukowski, R.-M. (1997) J. Immunol. 20, 479–487. [DOI] [PubMed] [Google Scholar]
- Motzer, R.-J. (2003) Crit. Rev. Oncol. Hematol. 46S, s33–s39. [DOI] [PubMed] [Google Scholar]
- Hofmockel, G., Tsatalpas, P., Muller, H., Dammrich, J., Poot, M., Maurer-Schultze, B., Muller-Hermelink, H.-K., Frohmuller, H.-G. & Bassukas, I.-D. (1995) Cancer 76, 296–306. [DOI] [PubMed] [Google Scholar]
- Shimazui, T., Oosterwijk, E., Akaza, H., Bringuier, P., Ruijter, E., van Berkel, H., Wakka, J.-O., van Bokhoven, A., Debruyne, F.-M. & Schalken, J.-A. (1998) Clin. Cancer Res. 4, 2419–2424. [PubMed] [Google Scholar]
Cited by
Items 201–300 of 796
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Pasello, G., Zago, G., Lunardi, F., Urso, L., Kern, I., Vlacic, G., Grosso, F., Mencoboni, M., Ceresoli, G. L., Schiavon, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy086 · Cited by 107
Biliary tract cancers: current knowledge, clinical candidates and future challenges
Tariq, N.-U.-A., McNamara, M. G., & Valle, J. W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s157092 · Cited by 120
Joosten, S. C., Hamming, L. C., Soetekouw, P. M. M. B., Aarts, M. J. B., Veeck, J., van Engeland, M., & Tjan‐Heijnen, V. C. G. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.11.002 · Cited by 121
Brauner, E., Gunda, V., Borre, P. V., Zurakowski, D., Kim, Y. S., Dennett, K. V., Amin, S., Freeman, G. J., & Parangi, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7839 · Cited by 111
Reiss, K. A., Forde, P. M., & Brahmer, J. R. (2014) · Immunotherapy · doi:10.2217/imt.14.9 · Cited by 111
Prognostic value of PDL1 expression in pancreatic cancer
Birnbaum, D. J., Finetti, P., Lopresti, A., Gilabert, M., Poizat, F., Turrini, O., Raoul, J., Delpéro, J., Moutardier, V., Birnbaum, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11685 · Cited by 121
The Role of Inflammation in Kidney Cancer
Chevez, A. R. D. V., Finke, J. H., & Bukowski, R. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_9 · Cited by 120
Khanna, S., Thomas, A., Abate‐Daga, D., Zhang, J., Morrow, B., Steinberg, S. M., Orlandi, A., Ferroni, P., Schlom, J., Guadagni, F., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.033 · Cited by 111
High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
Horita, S., Nomura, Y., Sato, Y., Shimamura, T., Iwata, S., & Nomura, N. (2016) · Scientific Reports · doi:10.1038/srep35297 · Cited by 110
Jin, J., & Zhao, Q. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00629-y · Cited by 100
PD-1 regulates extrathymic regulatory T-cell differentiation
Chen, X., Fosco, D., Kline, D. E., Meng, L., Nishi, S., Savage, P. A., & Kline, J. (2014) · European Journal of Immunology · doi:10.1002/eji.201344423 · Cited by 107
Dermime, S., & Afreen, S. (2014) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2013.09.005 · Cited by 101
Feng, Y., Shen, J. K., Gao, Y., Liao, Y., Cote, G. M., Choy, E., Chebib, I. A., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3576 · Cited by 108
Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege
Fecci, P. E., Heimberger, A. B., & Sampson, J. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0832 · Cited by 113
Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance
AlHossiny, M., Luo, L., Frazier, W. R., Steiner, N., Gusev, Y., Kallakury, B., Glasgow, E., Creswell, K., Madhavan, S., Kumar, R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2654 · Cited by 104
Targeting Costimulatory Molecules to Improve Antitumor Immunity
Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F., & Alesse, E. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/926321 · Cited by 98
Krambeck, A. E., Dong, H., Thompson, R. H., Kuntz, S. M., Lohse, C. M., Leibovich, B. C., Blute, M. L., Sebo, T. J., Cheville, J. C., Parker, A. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2129 · Cited by 114
Self-citationMukaigawa, T., Hayashi, R., Hashimoto, K., Ugumori, T., Hato, N., & Fujii, S. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24266 · Cited by 103
Messerschmidt, J. L., Prendergast, G. C., & Messerschmidt, G. L. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0282 · Cited by 109
Muenst, S., Soysal, S. D., Tzankov, A., & Hoeller, S. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.980235 · Cited by 97
PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis
Leite, K. R. M., Reis, S. T., Junior, J. P., Zerati, M., Gomes, D. D. O., Camara-Lopes, L. H. A., & Srougi, M. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0414-x · Cited by 103
Immunotherapy of cancers comes of age
Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 107
Prognostic Models and Algorithms in Renal Cell Carcinoma
Lane, B. R., & Kattan, M. W. (2008) · Urologic Clinics of North America · doi:10.1016/j.ucl.2008.07.003 · Cited by 104
Zhang, L., Qiu, M., Jin, Y., Ji, J., Li, B., Wang, X., Yan, S., Xu, R., & Yang, D. (2015) · PubMed Central · Cited by 111
Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
Zhao, J., Roberts, A., Wang, Z., Savage, J. T., & Ji, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00683-y · Cited by 119
Nivolumab for the treatment of cancer
Gunturi, A., & McDermott, D. F. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.991819 · Cited by 102
Cardiac Complications in Immune Checkpoint Inhibition Therapy
Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 103
Crispen, P. L., Boorjian, S. A., Lohse, C. M., Leibovich, B. C., & Kwon, E. D. (2008) · Cancer · doi:10.1002/cncr.23566 · Cited by 98
Self-citationPD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
Ji, M., Liu, Y., Li, Q., Li, X.-D., Zhao, W.-Q., Zhang, H., Zhang, X., Jiang, J.-T., & Wu, C.-P. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0373-0 · Cited by 92
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
Carlo, M. I., Voss, M. H., & Motzer, R. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.103 · Cited by 97
Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer
Saito, H., Kuroda, H., Matsunaga, T., Osaki, T., & Ikeguchi, M. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23281 · Cited by 94
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
Fay, A. P., Signoretti, S., Callea, M., Teló, G. H., McKay, R. R., Song, J., Carvo, I., Lampron, M. E., Kaymakcalan, M. D., Poli‐de‐Figueiredo, C. E., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0047-3 · Cited by 99
The complex role of B7 molecules in tumor immunology
Seliger, B., Marincola, F. M., Ferrone, S., & Abken, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.010 · Cited by 91
Basics of PD-1 in self-tolerance, infection, and cancer immunity
Chikuma, S. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-0958-0 · Cited by 98
The targeting of immunosuppressive mechanisms in hematological malignancies
Andersen, M. H. (2014) · Leukemia · doi:10.1038/leu.2014.108 · Cited by 97
Lowrance, W. T., Thompson, R. H., Yee, D. S., Kaag, M. G., Donat, S. M., & Russo, P. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08706.x · Cited by 102
Self-citationRaninga, P. V., Lee, A. C. H., Sinha, D., Shih, Y., Mittal, D., Makhale, A., Bain, A. L., Nanayakkara, D. M., Tonissen, K. F., Kalimutho, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32410 · Cited by 94
Maruse, Y., Kawano, S., Jinno, T., Matsubara, R., Goto, Y., Kaneko, N., Sakamoto, T., Hashiguchi, Y., Moriyama, M., Toyoshima, T., et al. (2018) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2018.01.004 · Cited by 98
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
Hu, Z. I., Ho, A. Y., & McArthur, H. L. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.029 · Cited by 90
Feng, E., Zheng, T., He, X., Chen, J., & Tian, Y. (2018) · Science Advances · doi:10.1126/sciadv.aau3494 · Cited by 87
Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage
Thompson, R. H., Zang, X., Lohse, C. M., Leibovich, B. C., Slovin, S. F., Reuter, V. E., Cheville, J. C., Blute, M. L., Russo, P., Kwon, E. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0869 · Cited by 89
Self-citationCarretero-González, A., Lora, D., Martín-Sobrino, I., Sanz, I. S., Bourlon, M. T., Herranz, U. A., Chanzá, N. M., Castellano, D., & de Velasco, G. (2020) · Cancers · doi:10.3390/cancers12071945 · Cited by 92
Webster, W. S., Lohse, C. M., Thompson, R. H., Dong, H., Frigola, X., Dicks, D. L., Sengupta, S., Frank, I., Leibovich, B. C., Blute, M. L., et al. (2006) · Cancer · doi:10.1002/cncr.21951 · Cited by 82
Self-citationPrognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
Yokoyama, S., Miyoshi, H., Nakashima, K., Shimono, J., Hashiguchi, T., Mitsuoka, M., Takamori, S., Akagi, Y., & Ohshima, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0434 · Cited by 88
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
Long, J., Zhang, Q., & Rongxin, Z. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0086 · Cited by 91
Bojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 82
Ramsey, S., Lamb, G. W. A., Aitchison, M., & McMillan, D. C. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07363.x · Cited by 84
Ahmad, S. M., Olofsson, G. H., Met, Ö., Donia, M., Frøsig, T. M., Larsen, S. K., Klausen, T. W., Svane, I. M., & Andersen, M. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3507 · Cited by 84
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
Suo, A., Chan, Y., Beaulieu, C., Kong, S., Cheung, W. Y., Monzon, J. G., Smylie, M., Walker, J., Morris, D., & Cheng, T. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0674 · Cited by 83
“The association of the development of irAEs with response and survival does not preclude that PD-1 blockade acts primarily in the TME to stimulate antitumor CD8-positive T cell responses, as a pre-existing T cell response within the TME is likely necessary in mounting an adequate systemic immune response from PD-1 che…”
BackgroundInfluentialXu, F., Xu, L., Wang, Q., An, G., Feng, G., & Liu, F. (2015) · PubMed Central · Cited by 93
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
Lee, J., Han, Y., Wang, W., Jo, H., Kim, H., Kim, S., Yang, K., Kim, S., Dhanasekaran, D. N., & Song, Y. S. (2021) · Biomolecules · doi:10.3390/biom11081107 · Cited by 95
Immunotherapy of melanoma: Present options and future promises
Rotte, A., Bhandaru, M., Zhou, Y., & McElwee, K. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9542-0 · Cited by 85
Prognostic factors and selection for clinical studies of patients with kidney cancer
Lam, J. S., Klatte, T., Kim, H. L., Patard, J., Breda, A., Zisman, A., Pantuck, A. J., & Figlin, R. A. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.08.003 · Cited by 92
State of the art in anti-cancer mAbs
Chiavenna, S. M., Jaworski, J. P., & Vendrell, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-016-0311-y · Cited by 82
PD-1 and PD-L1 expression in bone and soft tissue sarcomas
Torabi, A., Amaya, C. N., Wians, F. H., & Bryan, B. A. (2017) · Pathology · doi:10.1016/j.pathol.2017.05.003 · Cited by 80
Cancer vaccines: Looking to the future
Yaddanapudi, K., Mitchell, R. A., & Eaton, J. W. (2013) · OncoImmunology · doi:10.4161/onci.23403 · Cited by 93
Oguejiofor, K., Galletta, H., Dovedi, S. J., Roberts, D. L., Stern, P. L., & West, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14796 · Cited by 82
The expression, function, and clinical relevance of B7 family members in cancer
Seliger, B., & Quandt, D. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1293-6 · Cited by 85
Immunoregulatory role of melatonin in cancer
Moradkhani, F., Moloudizargari, M., Fallah, M., Asghari, N., Khoei, H. H., & Asghari, M. H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29036 · Cited by 82
PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments
Valentini, A. M., Pinto, F. D., Cariola, F., Guerra, V., Giannelli, G., Caruso, M. L., & Pirrelli, M. (2018) · Oncotarget · doi:10.18632/oncotarget.24196 · Cited by 84
MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells
Zuo, Y., Zheng, W., Liu, J., Tang, Q., Wang, S. S., & Yang, X. (2019) · Neoplasma · doi:10.4149/neo_2019_190202n106 · Cited by 79
Raufi, A. G., & Klempner, S. J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.037 · Cited by 91
Leng, C., Li, Y., Qin, J., Ma, J., Liu, X., Cui, Y., Sun, H., Wang, Z., Hua, X., Yu, Y., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4435 · Cited by 81
Immunoregulatory role of B7-H1 in chronicity of inflammatory responses.
Dong, H., & Chen, X. (2006) · PubMed · Cited by 85
Self-citationTargeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas
Fitz, C. D. V., Li, G., & Wong, A. J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.177 · Cited by 77
Gupta, S., Cheville, J. C., Jungbluth, A. A., Zhang, Y., Zhang, L., Chen, Y., Tickoo, S. K., Fine, S. W., Gopalan, A., Al‐Ahmadie, H. A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0269-x · Cited by 76
Self-citationProgrammed death-1 checkpoint blockade in acute myeloid leukemia
Sehgal, A. R., Whiteside, T. L., & Boyiadzis, M. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1051028 · Cited by 82
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13081 · Cited by 70
Ghosh, S., Shah, P. A., & Johnson, F. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147889 · Cited by 79
Tumor immune microenvironment characterization and response to anti-PD-1 therapy.
Santarpía, M., & Karachaliou, N. (2015) · PubMed · doi:10.7497/j.issn.2095-3941.2015.0022 · Cited by 47
Melzer, M., Lopez-Martinez, A., & Altomonte, J. (2017) · Biomedicines · doi:10.3390/biomedicines5010008 · Cited by 78
de Vicente, J. C., Rodríguez‐Santamarta, T., Rodrigo, J. P., Blanco‐Lorenzo, V., Allonca, E., & Garcia-Pedrero, J. M. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0779 · Cited by 78
Mori, K., Abufaraj, M. M., Mostafaei, H., Quhal, F., Fajković, H., Remzi, M., Karakiewicz, P. I., Egawa, S., Schmidinger, M., Shariat, S. F., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.10.006 · Cited by 75
Aghapour, S. A., Torabizadeh, M., Bahreiny, S. S., Saki, N., Far, M. A. J., Avarvand, A. Y., Ghasemi, K. D. M., Aghaei, M., Abolhasani, M. M., Sharifani, M. S., et al. (2024) · Iranian Journal of Blood and Cancer · doi:10.61186/ijbc.16.2.84 · Cited by 72
Sun, J., Xu, K., Wu, C., Wang, Y., Hu, Y., Zhu, Y., Chen, Y., Shi, Q., Yu, G., & Zhang, X. (2006) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00701.x · Cited by 74
Mkrtichyan, M., Chong, N., Abu Eid, R., Wallecha, A., Singh, R., Rothman, J., & Khleif, S. N. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-15 · Cited by 68
B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence
Routh, J. C., Ashley, R. A., Sebo, T. J., Lohse, C. M., Husmann, D. A., Kramer, S. A., & Kwon, E. D. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.01.056 · Cited by 71
Self-citationDai, C., Geng, R., Wang, C., Wong, A., Qing, M., Hu, J., Sun, Y. L., Lo, A. W. I., & Li, J. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.004 · Cited by 69
Xie, G., Li, W., Li, R., Wu, K., Zhao, E., Zhang, Y., Zhang, P., Shi, L., Wang, D., Yin, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168822 · Cited by 70
A comprehensive review of immunotherapies in prostate cancer
Maia, M. C., & Hansen, A. R. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.026 · Cited by 71
May, K. F., Gulley, J. L., Drake, C. G., Dranoff, G., & Kantoff, P. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3402 · Cited by 73
Zhang, X., Yin, X., Zhang, H., Sun, G., Yang, Y., Chen, J., Zhu, X., Zhao, P., Zhao, J., Liu, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5578-4 · Cited by 72
Chowdhury, F., Dunn, S. N., Mitchell, S. A., Mellows, T., Ashton‐Key, M., & Gray, J. C. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1029701 · Cited by 78
Biomarkers to predict prognosis and response to checkpoint inhibitors
Yuasa, T., Masuda, H., Yamamoto, S., Numao, N., & Yonese, J. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1122-1 · Cited by 69
Botticelli, A., Cirillo, A., Scagnoli, S., Cerbelli, B., Strigari, L., Cortellini, A., Pizzuti, L., Vici, P., Galitiis, F. D., Pietro, F. R. D., et al. (2020) · Vaccines · doi:10.3390/vaccines8020203 · Cited by 69
The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation
Blank, C. U. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000054 · Cited by 68
PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+cytotoxic T cells
Waeckerle‐Men, Y., Starke, A., & Wüthrich, R. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl818 · Cited by 67
Prognostic value of PD -L1 expression in patients with primary solid tumors
Xiang, X. J., Yu, P., Long, D., Liao, X.-L., Zhang, S., You, X., Zhong, J., & Li, L. (2017) · Oncotarget · doi:10.18632/oncotarget.23580 · Cited by 67
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
Koopmans, I., Hendriks, D., Samplonius, D. F., van Ginkel, R. J., Heskamp, S., Wierstra, P. J., Bremer, E., & Helfrich, W. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466016 · Cited by 69
Mechanism of T cell exhaustion in a chronic environment
Jin, H.-T., Jeong, Y. H., Park, H.-J., & Ha, S. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.4.217 · Cited by 73
Macrophage colony-stimulating factor and cancer: a review
Chockalingam, S., & Ghosh, S. S. (2014) · Tumor Biology · doi:10.1007/s13277-014-2627-0 · Cited by 67
AiErken, N., Shi, H.-J., Zhou, Y., Shao, N., Zhang, J., Shi, Y., Yuan, Z.-Y., & Lin, Y. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.20868 · Cited by 71
Berntsson, J., Eberhard, J., Nodin, B., Leandersson, K., Larsson, A. H., & Jirström, K. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465165 · Cited by 62
PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
Frydenlund, N., & Mahalingam, M. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.06.012 · Cited by 67
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
Zhu, J., Wen, H., Bi, R., Wu, Y., & Wu, X. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e77 · Cited by 62
Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
Wang, L., Ma, Q., Yao, R., & Liu, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106088 · Cited by 63
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
Ahmad, S. M., Olofsson, G. H., Svane, I. M., & Andersen, M. H. (2013) · OncoImmunology · doi:10.4161/onci.23991 · Cited by 60
Predicting outcomes in renal cell carcinoma
Lane, B. R., & Kattan, M. W. (2005) · Current Opinion in Urology · doi:10.1097/01.mou.0000178336.94991.17 · Cited by 60
Autoimmunity and Immunotherapy for Cancer
Koon, H. B., & Atkins, M. B. (2006) · New England Journal of Medicine · doi:10.1056/nejme058307 · Cited by 60
Metadata
- Authors
- Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-11-29
- Volume
- 101
- Issue
- 49
- Pages
- 17174-17179
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC534606
- OpenAlex
- W4230861071
- Cited by
- 776
- References
- 48
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 15 · 2023: 29 · 2022: 32 · 2021: 42 · 2020: 51 · 2019: 60 · 2018: 57 · 2017: 76 · 2016: 65 · 2015: 69 · 2014: 57 · 2013: 29 · 2012: 28
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, renal cell carcinoma, tumor-infiltrating lymphocytes, tumor progression, prognostic factors, tumor immune evasion, T cell costimulation, immunotherapy targets, cancer mortality
- MeSH terms
- Carcinoma, Renal Cell, Follow-Up Studies, Humans, Immunity, Immunohistochemistry, Membrane Glycoproteins, Neoplasm Proteins, Peptides, Prognosis, Antigens, CD, Odds Ratio, Survival Analysis, Lymphocytes, Tumor-Infiltrating, B7-1 Antigen, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.